Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study-Reference-Cited by-同舟云学术

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study

Published:2020-12 Issue:12 Volume:9 Page:718-730
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Gupta Neeraj¹,Wang Xiaohui²,Offman Elliot²,Rich Benjamin²,Kerstein David¹,Hanley Michael¹,Diderichsen Paul M.²,Zhang Pingkuan¹,Venkatakrishnan Karthik¹

Affiliation:

1. Millennium Pharmaceuticals, Inc. Cambridge Massachusetts USA

2. Certara Princeton New Jersey USA

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12569

Reference39 articles.

1. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

2. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

3. Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

4. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

5. Brigatinib in crizotinib‐refractory ALK+ NSCLC: 2‐year follow‐up on systemic and intracranial outcomes in the phase 2 ALTA trial;Huber R.M.;J. Thorac. Oncol.,2020

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach;CPT: Pharmacometrics & Systems Pharmacology;2024-01-30

2. Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor;Clinical Pharmacokinetics;2023-07-26

3. Brigatinib pharmacokinetics in patients with chronic hepatic impairment;Investigational New Drugs;2023-04-13

4. Concentration QTc analysis of giredestrant: Overcoming QT/heart rate confounding in the presence of drug‐induced heart rate changes;Clinical and Translational Science;2023-02-22

5. A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐ Positive or ROS1 ‐Positive Solid Tumors;The Journal of Clinical Pharmacology;2023-01-27